MINISTRY OF HEALTH OF UZBEKISTAN
... 1. Removal, reduction of symptoms of myocardial ischemia, its main clinical manifestations - angina. 2. Improving the quality of life. 3. Improved prediction of coronary heart disease patients. The major directions in the treatment of ischemic heart disease: 1. The main principle of treatment - it's ...
... 1. Removal, reduction of symptoms of myocardial ischemia, its main clinical manifestations - angina. 2. Improving the quality of life. 3. Improved prediction of coronary heart disease patients. The major directions in the treatment of ischemic heart disease: 1. The main principle of treatment - it's ...
The effect of angiotensin converting enzyme inhibition on
... surgery. Experimental data show that angiotensin converting enzyme inhibition can reduce infarct size in dogs [16]. In this study captopril increased regional myocardial blood flow in the area of infarction, decreased mean arterial pressure and decreased left atrial pressure. Animals treated with ca ...
... surgery. Experimental data show that angiotensin converting enzyme inhibition can reduce infarct size in dogs [16]. In this study captopril increased regional myocardial blood flow in the area of infarction, decreased mean arterial pressure and decreased left atrial pressure. Animals treated with ca ...
Understanding Carotid Artery Stenting
... Tell your physician about any medications you are taking. Take all your prescription medications with you. Let your physician know about any allergies you may have, especially to contrast dye or iodine, to metals (cobalt, chromium, nickel, titanium or stainless steel) or to plastics (polyurethane). ...
... Tell your physician about any medications you are taking. Take all your prescription medications with you. Let your physician know about any allergies you may have, especially to contrast dye or iodine, to metals (cobalt, chromium, nickel, titanium or stainless steel) or to plastics (polyurethane). ...
Cardiogenic Shock Complicating Acute Myocardial
... AHA and ESC guidelines [12], should be adopted: it’s is the most efficient therapy to restore coronary flow in the infarct- related artery. The GUSTO-I investigators [13] found that while PCI was performed in only 19% of the 2972 patients with CS, this translated into a mortality rate of 31% compare ...
... AHA and ESC guidelines [12], should be adopted: it’s is the most efficient therapy to restore coronary flow in the infarct- related artery. The GUSTO-I investigators [13] found that while PCI was performed in only 19% of the 2972 patients with CS, this translated into a mortality rate of 31% compare ...
Recent Research Topics from the Japanese Society of Nuclear
... submitted their published work prior to the meeting and the top 3 candidates presented their work at the YIA session. Although the previous format provided excellent data to the audiences, the presented data was actually a number of years old by the time it was presented. Therefore, last year, the J ...
... submitted their published work prior to the meeting and the top 3 candidates presented their work at the YIA session. Although the previous format provided excellent data to the audiences, the presented data was actually a number of years old by the time it was presented. Therefore, last year, the J ...
Aortic stenosis, angina, and coronary artery disease - Heart
... normal coronary vessels. Indeed, studies by Fallen, Elliott, and Gorlin (I967) have shown evidence of ischaemia in the ventricle of patients with aortic stenosis and patent coronary arteries. That even a normal coronary tree may be inadequate to meet these exaggerated demands is also attested to by ...
... normal coronary vessels. Indeed, studies by Fallen, Elliott, and Gorlin (I967) have shown evidence of ischaemia in the ventricle of patients with aortic stenosis and patent coronary arteries. That even a normal coronary tree may be inadequate to meet these exaggerated demands is also attested to by ...
Acute Coronary Syndrome
... So why is platelet inhibition so important in ACS? Over time atherosclerotic lesions develop in the coronary artery. The endothelial cells become damaged or dysfunctional during atherosclerosis, which further create an inflammatory environment by attracting more platelets. In return, this makes the ...
... So why is platelet inhibition so important in ACS? Over time atherosclerotic lesions develop in the coronary artery. The endothelial cells become damaged or dysfunctional during atherosclerosis, which further create an inflammatory environment by attracting more platelets. In return, this makes the ...
national institute for clinical excellence
... Hypercholesterolaemia is defined as the presence of high concentrations of cholesterol in the blood. Primary hypercholesterolaemia is associated with an underlying genetic cause; this may be a specific genetic defect, as in familial hypercholesterolaemia (FH), or more commonly, polygenic hypercholes ...
... Hypercholesterolaemia is defined as the presence of high concentrations of cholesterol in the blood. Primary hypercholesterolaemia is associated with an underlying genetic cause; this may be a specific genetic defect, as in familial hypercholesterolaemia (FH), or more commonly, polygenic hypercholes ...
Kein Folientitel
... MRI Marker Active MRI Stents & Vena Cava Filter -brief introductionAndreas Melzer University of Applied Sciences Gelsenkirchen Institute for Innovative Technologies and Management in Medicine, INSITE med. & Biophan Europe GmbH ...
... MRI Marker Active MRI Stents & Vena Cava Filter -brief introductionAndreas Melzer University of Applied Sciences Gelsenkirchen Institute for Innovative Technologies and Management in Medicine, INSITE med. & Biophan Europe GmbH ...
Fluvastatin for Prevention of Cardiac Events Following Successful
... Interventions Patients were randomly assigned to receive treatment with fluvastatin, 80 mg/d (n = 844), or matching placebo (n = 833) at hospital discharge for 3 to 4 years. Main Outcome Measure Survival time free of MACE, defined as cardiac death, nonfatal myocardial infarction, or reintervention p ...
... Interventions Patients were randomly assigned to receive treatment with fluvastatin, 80 mg/d (n = 844), or matching placebo (n = 833) at hospital discharge for 3 to 4 years. Main Outcome Measure Survival time free of MACE, defined as cardiac death, nonfatal myocardial infarction, or reintervention p ...
Paediatric cardiac transplantation: history
... Renal dysfunction: change to Mycophenolate Mofetil and lower the dose of CSA ...
... Renal dysfunction: change to Mycophenolate Mofetil and lower the dose of CSA ...
Newer anti anginals
... Patients with limiting angina -13.8% of the trial population. 24% reduction in the primary endpoint [cardiovascular mortality or hospitalization for fatal and non-fatal myocardial infarction (MI) or heart failure HR, 0.76; 95% CI, 0.58–1.00] and a 42% reduction in hospitalization for MI (HR, 0.58; 9 ...
... Patients with limiting angina -13.8% of the trial population. 24% reduction in the primary endpoint [cardiovascular mortality or hospitalization for fatal and non-fatal myocardial infarction (MI) or heart failure HR, 0.76; 95% CI, 0.58–1.00] and a 42% reduction in hospitalization for MI (HR, 0.58; 9 ...
Pharmacologic management of UA/NSTEMI
... • Rest angina: usually > 20 min • New onset angina: ≥CCS class III • Increasing angina: more frequent, longer in duration, or lower in threshold • Should determine short-term risk of death or nonfatal MI based on history, character of pain, clinical findings, ECG changes, and presence of cardiac mar ...
... • Rest angina: usually > 20 min • New onset angina: ≥CCS class III • Increasing angina: more frequent, longer in duration, or lower in threshold • Should determine short-term risk of death or nonfatal MI based on history, character of pain, clinical findings, ECG changes, and presence of cardiac mar ...
PDF - SAS Publishers
... atheromatous lesion is recognized [11] and such slow coronary flow has been attributed to ventricular tachycardia [12]. Excessive sympathoadrenal discharges associated with marijuana smoking [13] could possibly increase risk for arrhythmogenesis. CB1 receptors have been shown to promote oxidative st ...
... atheromatous lesion is recognized [11] and such slow coronary flow has been attributed to ventricular tachycardia [12]. Excessive sympathoadrenal discharges associated with marijuana smoking [13] could possibly increase risk for arrhythmogenesis. CB1 receptors have been shown to promote oxidative st ...
Unstable Angina and Non–ST-Segment Elevation Myocardial
... trials. The Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trial18 randomized more than 12,000 patients with UA/NSTEMI to receive clopidogrel or placebo in addition to aspirin. Patients were followed for three to 12 months. In the CURE trial, death, myocardial infarction, ...
... trials. The Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trial18 randomized more than 12,000 patients with UA/NSTEMI to receive clopidogrel or placebo in addition to aspirin. Patients were followed for three to 12 months. In the CURE trial, death, myocardial infarction, ...
Guidelines Appendix 7. Perioperative Management Of Clopidogrel
... Combination with aspirin produces synergistic effects as it blocks complementary pathways involved in platelet aggregation ...
... Combination with aspirin produces synergistic effects as it blocks complementary pathways involved in platelet aggregation ...
PDF - Circulation
... which may increase systemic output do so at the expense of increased myocardial oxygen demand and may further impair myocardial contraction in ischemic areas."' In both situations, the desired physiologic response possibly could be achieved by vasodilator therapy. Reduction in systemic resistance in ...
... which may increase systemic output do so at the expense of increased myocardial oxygen demand and may further impair myocardial contraction in ischemic areas."' In both situations, the desired physiologic response possibly could be achieved by vasodilator therapy. Reduction in systemic resistance in ...
Guideline for the use of clopidogrel in combination
... sufficient to recommend the use of clopidogrel in combination with aspirin in moderate to high-risk patients with non-ST elevation acute coronary syndrome for 12 months. Subgroup analysis of the CURE study has shown that the greatest benefits occurred within the first three months of treatment. Howe ...
... sufficient to recommend the use of clopidogrel in combination with aspirin in moderate to high-risk patients with non-ST elevation acute coronary syndrome for 12 months. Subgroup analysis of the CURE study has shown that the greatest benefits occurred within the first three months of treatment. Howe ...
Hiccups as a myocardial ischemia symptom
... angiography. Advanced coronary artery abnormalities were shown: left main coronary artery – 40% distal stenosis; left anterior descending artery (LAD) – significant stenosis in proximal segment and occlusion on the level of I diagonal branch (significantly stenosed in the opening), distal LAD segmen ...
... angiography. Advanced coronary artery abnormalities were shown: left main coronary artery – 40% distal stenosis; left anterior descending artery (LAD) – significant stenosis in proximal segment and occlusion on the level of I diagonal branch (significantly stenosed in the opening), distal LAD segmen ...
What Is Coronary Artery Disease?
... coronary artery disease include balloon angioplasty (PTCA) and stent or drug-eluting stent placement. These procedures are considered nonsurgical because they are done by a cardiologist through a tube or catheter inserted into a blood vessel, rather than by a surgeon through an incision. Several typ ...
... coronary artery disease include balloon angioplasty (PTCA) and stent or drug-eluting stent placement. These procedures are considered nonsurgical because they are done by a cardiologist through a tube or catheter inserted into a blood vessel, rather than by a surgeon through an incision. Several typ ...
What Is Coronary Artery Disease?
... coronary artery disease include balloon angioplasty (PTCA) and stent or drug-eluting stent placement. These procedures are considered nonsurgical because they are done by a cardiologist through a tube or catheter inserted into a blood vessel, rather than by a surgeon through an incision. Several typ ...
... coronary artery disease include balloon angioplasty (PTCA) and stent or drug-eluting stent placement. These procedures are considered nonsurgical because they are done by a cardiologist through a tube or catheter inserted into a blood vessel, rather than by a surgeon through an incision. Several typ ...
Myocardial Perfusion SPECT: Current Concepts
... > the rate of cardiac events in persons with a pathological (high-risk) MPS increases with increasing severity of CAD; > the frequency of cardiac events in persons with a normal (low-risk) MPS is nearly always below 2% per year, regardless of the stage of CAD that is present, i.e., even in patients ...
... > the rate of cardiac events in persons with a pathological (high-risk) MPS increases with increasing severity of CAD; > the frequency of cardiac events in persons with a normal (low-risk) MPS is nearly always below 2% per year, regardless of the stage of CAD that is present, i.e., even in patients ...
Coronary Sinus
... showing any of the intimal hyperplasia of the coronary sinus system. The intima was a thin layer of endothelium (fig. 2E). The external elastic membrane was thin and the adventitia was composed of collagenous fibers. Sections taken from the interventricular septum showed structures comparable to tho ...
... showing any of the intimal hyperplasia of the coronary sinus system. The intima was a thin layer of endothelium (fig. 2E). The external elastic membrane was thin and the adventitia was composed of collagenous fibers. Sections taken from the interventricular septum showed structures comparable to tho ...
cine-angiography of the coronary circulation in living - Heart
... then slow enough to improve the coronary artery filling. The short-acting drug edrophonium chloride (tensilon) was also tried in doses up to 20 mg., without atropine, but the reduction in pulse rate did not exceed 10 per cent and was without significant effect on the coronary filling. Gregg and Sabi ...
... then slow enough to improve the coronary artery filling. The short-acting drug edrophonium chloride (tensilon) was also tried in doses up to 20 mg., without atropine, but the reduction in pulse rate did not exceed 10 per cent and was without significant effect on the coronary filling. Gregg and Sabi ...
Drug-eluting stent
A drug-eluting stent (DES) is a peripheral or coronary stent (a scaffold) placed into narrowed, diseased peripheral or coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombi), could otherwise block the stented artery, a process called restenosis. The stent is usually placed within the peripheral or coronary artery by an interventional cardiologist or interventional radiologist during an angioplasty procedure.Drug-eluting stents in current clinical use were approved by the FDA after clinical trials showed they were statistically superior to bare-metal stents for the treatment of native coronary artery narrowings, having lower rates of major adverse cardiac events (usually defined as a composite clinical endpoint of death + myocardial infarction + repeat intervention because of restenosis). The first drug-eluting stents to be approved in Europe and the U.S. were coated with paclitaxel or an mTOR inhibitor, such as sirolimus.